Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations

• DOI: 10.1111/resp.14309
• Publication Date: 2022-06-16T01:33:50Z
• Authors: Yan Li; Pingshu Zhang; Zhijie An; Chenyan Yue; Yamin Wang; Yunqiu Liu; Xiaodong Yuan; Ying Ma; Keli Li; Zundong Yin; Liye Wang; Huaqing Wang
• Keywords: COVID-19; Pneumonia; Pneumonia, Pneumococcal; Pneumococcal Infections; 3. Good health; Pneumococcal Vaccines; Pulmonary Disease, Chronic Obstructive; 03 medical and health sciences; 0302 clinical medicine; Influenza Vaccines; Influenza, Human; Humans

Abstract Background and objective Single‐study evidence of separate combined effectiveness influenza pneumococcal vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To fill this gap, we studied the trivalent seasonal vaccine (TIV) 23‐valent polysaccharide (PPSV23), separately together, at preventing adverse COPD outcomes. Methods Our study used a self‐controlled, before‐and‐after cohort design to assess TIV PPSV23 patients. Patients were recruited from hospitals Tangshan City, Hebei Province, China. Subjects self‐selected into one three schedules: group, group TIV&PPSV23 group. We physician‐completed, medical record‐verified questionnaire obtain data on acute exacerbations (AECOPD), pneumonia related hospitalization. Vaccine was determined by comparing outcomes before after vaccination, controlling for potential confounding using Cox regression. Results 474 patients, whom 109 received TIV, 69 296 PPSV23. Overall AECOPD, hospitalization respectively 70%, 59% 58% group; 54%, 53% 46% 72%, 73% 69% The without COVID‐19 non‐pharmaceutical intervention period 84%, 77% 88% 63%, 74% 66% 82%, 83% 91% Conclusion Influenza can effectively reduce risk Effectiveness AECOPD greatest.